Cost of Revenue Trends: Pfizer Inc. vs United Therapeutics Corporation

Pfizer vs. United Therapeutics: A Decade of Cost Dynamics

__timestampPfizer Inc.United Therapeutics Corporation
Wednesday, January 1, 20149577000000125883000
Thursday, January 1, 2015964800000069036000
Friday, January 1, 20161232900000072700000
Sunday, January 1, 201711240000000105700000
Monday, January 1, 201811248000000198700000
Tuesday, January 1, 201910219000000117600000
Wednesday, January 1, 20208692000000108100000
Friday, January 1, 202130821000000122500000
Saturday, January 1, 202234344000000146700000
Sunday, January 1, 202329687000000257500000
Monday, January 1, 202417851000000
Loading chart...

Cracking the code

Cost of Revenue Trends: A Tale of Two Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Pfizer Inc., a global leader, has seen its cost of revenue fluctuate significantly over the past decade. From 2014 to 2023, Pfizer's cost of revenue surged by over 200%, peaking in 2022. This reflects the company's aggressive expansion and investment in new technologies. In contrast, United Therapeutics Corporation, a niche player, maintained a relatively stable cost structure, with a modest increase of around 100% over the same period. This stability highlights their focused approach in specialized markets. The stark contrast between these two companies underscores the diverse strategies within the pharmaceutical sector. As Pfizer navigates the complexities of a broad portfolio, United Therapeutics remains steadfast in its specialized niche, offering a fascinating study in strategic financial management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025